The broad markets are hitting new highs as we are closing out 2016 in the wake of the U.S. presidential election. Also after a recent OPEC meeting, crude oil is now above the $50 mark. But despite these solid tailwinds there are still companies holding back this rally. 24/7 Wall Street has picked out a few companies posting some of the largest losses for the past week. Some companies are hitting lows and creating huge shareholder losses.
We have included a little color on why each stock has lagged, as well as a recent trading history, consensus analyst price target and a 52-week trading range.
Shares of Nivalis Therapeutics Inc. (NASDAQ: NVLS) crumbled on Tuesday after the company gave an update on its mid-stage cystic fibrosis (CF) trial. Specifically, the company announced topline results from its Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi.
There were no dose limiting toxicities, and cavosonstat was well tolerated at all doses in the trial. The trial failed, however, to demonstrate benefit in absolute change in percentage predicted FEV1, the trial’s primary endpoint, or in sweat chloride reduction at 12 weeks.
Although Nivalis’ study did not meet the primary endpoint, these data help inform the overall body of CF research, and the company remains dedicated to completing its current clinical CF research program.
The stock closed the past week down 67% at $2.07. It has a Thomson Reuters consensus analyst price target of $14.06 and a 52-week trading range of $2.02 to $9.35.
Late on Wednesday, Guess Inc. (NYSE: GES) reported fiscal third-quarter financial results. The company said that it had $0.11 in earnings per share (EPS) and $536.3 million in revenue. Thomson Reuters consensus estimates had called for $0.14 in EPS and revenue of $548.37 million. The same period of last year reportedly had EPS of $0.15 and $520.96 million in revenue.
Americas Retail revenues decreased 4.7% in U.S. dollars and 4.6% in constant currency. Retail comp sales including e-commerce decreased 4.9% in U.S. dollars and 4.8% in constant currency.
On the international side, Europe revenues increased 16.4% in U.S. dollars and 16.8% in constant currency. Asia revenues increased 9.8% and 6.4% in constant currency.
In terms of the outlook for the fiscal fourth-quarter, the company expects EPS to be in the range of $0.40 to $0.50 and consolidated revenues to grow between 3.5% and 7.5%. The consensus estimates call for $723.89 million in revenue.
Shares dropped by 18.6% last week, closing the week at $12.91, with a consensus price target of $15.80 and a 52-week range of $12.90 to $22.84.
Clearside Biomedical Inc. (NASDAQ: CLSD) has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering. The company did not give any pricing details in the filing, but it values the offering up to $86.25 million, with an overallotment option valued up to $11.25 million.
The underwriters for this offering are JPMorgan, Cowen, Stifel and Wedbush PacGrow.
This late-stage clinical biopharmaceutical company is developing first-in-class drug therapies to treat blinding diseases of the eye. The current product candidates focus on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space (SCS), adjacent to the choroid, using the proprietary SCS Microinjector.
Over the past week, shares dropped about 27% to close out at $15.62. The consensus price target is $25.00, and the 52-week range is $5.65 to $25.08.